Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.
Tamer OthmanJohn H BairdStacy PakMatthew G MeiAlex F HerreraJoshua MansourGeoffrey ShouseFiroozeh SahebiRicardo SpielbergerJi-Lian CaiLeonardo FarolJames GodfreyAvyakta KallamTycel PhillipsLeslie PopplewellTanya SiddiqiStephen FormanL Elizabeth Elizabeth BuddePublished in: British journal of haematology (2024)